Scarica l'app Stockscreener
1.20
0.84%
0.01
Precedente Chiudi:
$1.19
Aprire:
$1.19
Volume 24 ore:
39,716
Relative Volume:
0.16
Capitalizzazione di mercato:
$5.26M
Reddito:
-
Utile/perdita netta:
$-6.78M
Rapporto P/E:
-0.3359
EPS:
-3.5729
Flusso di cassa netto:
$-4.67M
1 W Prestazione:
-18.55%
1M Prestazione:
-11.76%
6M Prestazione:
-6.25%
1 anno Prestazione:
-60.00%
Intervallo 1D:
$1.17
$1.27
Intervallo di 1 settimana:
$1.14
$1.47
Portata 52W:
$0.9205
$3.58
Clearmind Medicine Inc Stock (CMND) Company Profile
Nome
Clearmind Medicine Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta CMND con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.20 | 5.26M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Clearmind Medicine Inc Borsa (CMND) Ultime notizie
Clearmind Medicine (NASDAQ:CMND) Shares Up 3.5% – Time to Buy? - Defense World
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format - The Manila Times
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI-Based Alcohol Substitute in ActivCrystal? Format - Marketscreener.com
Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Rail Vision unveils new SaaS platform for rail safety By Investing.com - Investing.com South Africa
Rail Vision unveils new SaaS platform for rail safety - Investing.com
Premium Access Slides: Current Tailwind % Scores and Relative Strength Rank & Trend Reports in a Google Slideshow? - substack.com
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Clearmind Medicine (NASDAQ:CMND) Shares Down 12.3% – What’s Next? - Defense World
Bright Minds stock cools amid psychedelic volatility (DRUG:NASDAQ) - Seeking Alpha
Clearmind Medicine Inc [CMND] Revenue clocked in at $0.00 million, down -51.60% YTD: What’s Next? - The DBT News
Clearmind advances trial for alcohol use disorder therapy - Investing.com
Why Aehr Test Systems Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Clearmind advances trial for alcohol use disorder therapy By Investing.com - Investing.com Australia
Clearmind Medicine Inc (NASDAQ: CMND): Is Its Value Too High Compared To Others? - Stocks Register
Clearmind Medicine Inc Inc. (CMND) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Examining CMND’s book value per share for the latest quarter - US Post News
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site - Marketscreener.com
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 - Investing.com
Rail Vision secures $20 million equity deal with Yorkville - Investing.com
SciSparc gains as Clearmind partnership yields 3 new international patent applications - MSN
Clearmind Medicine Completed Type A Meeting with the FDA - GlobeNewswire
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - Marketscreener.com
Clearmind Medicine appoints new board member - Investing.com
Clearmind, SciSparc slide amid weight-loss study results - MSN
Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes - MSN
Clearmind Medicine patents new addiction treatment - Investing.com India
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
SciSparc Unveils Breakthrough Ibogaine Therapy Patent - TipRanks
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering - The Bakersfield Californian
SciSparc-Clearmind Medicine Collaboration Announces the - GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - StockTitan
Contrasting Clearmind Medicine (NASDAQ:CMND) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Clearmind Medicine files patent for PTSD treatment compounds - Investing.com
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment - Morningstar
SciSparc shares up on patents filed for psychedelic compounds with Clearmind - MSN
SciSparc and Clearmind Innovate Mental Health Treatment - TipRanks
Clearmind Medicine files patent for novel MDMA therapy - Investing.com
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Yahoo Finance UK
SciSparc-Clearmind Medicine Collaboration Leads to - GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent ... - The Bakersfield Californian
A History of Outperforming Analyst Forecasts and Beating the Odds: Clearmind Medicine Inc (CMND) - SETE News
Financial Metrics Check: Clearmind Medicine Inc (CMND)’s Ratios for Trailing Twelve Months - The Dwinnex
Clearmind and SciSparc file patent for ketamine-based therapy - Investing.com
SciSparc and Clearmind Innovate in Mental Health Therapy - TipRanks
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment - Morningstar
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination - Yahoo Finance
Clearmind Biomedical Announces FDA Clearance and First U.S. Surgery of the Neuroblade System for Minimally Invasive Neurosurgery - PR Newswire
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive
CMND’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Clearmind receives patent for drug to treat binge behavior - Green Market Report
Clearmind Medicine Inc Azioni (CMND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):